Home › NDC Lookup › RxCUI directory › RxCUI 2626751

22000 MG anacaulase-bcdb 0.088 MG/MG Topical Gel — RxCUI 2626751

RxNorm drug concept · Semantic clinical drug
RxCUI 2626751 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2626751
Official name22000 MG anacaulase-bcdb 0.088 MG/MG Topical Gel
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asanacaulase-bcdb 8.8 % Topical Gel, 22 GM
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 22000 MG anacaulase-bcdb 0.088 MG/MG Topical Gel Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 22000 MG anacaulase-bcdb 0.088 MG/MG Topical Gel RxCUI 2626751

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Anacaulase 2626723
    • Anacaulase-bcdb 2626722
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nexobrid 2626743
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Anacaulase Topical Gel 2626740
    • Anacaulase-bcdb Topical Gel 2646045
    • Anacaulase Topical Product 2626739
    • Anacaulase-bcdb Topical Product 2662717
    • Anacaulase Topical Gel [Nexobrid] 2626746
    • Anacaulase-bcdb Topical Gel [Nexobrid] 2654459
    • Nexobrid Topical Product 2626745
    • Topical Gel 346286
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Anacaulase-bcdb 0.088 MG/MG SCDC · 2626750
  • Anacaulase Topical Gel SCDF · 2626740
  • Anacaulase-bcdb Topical Gel SCDFP · 2646045
  • Anacaulase Topical Product SCDG · 2626739
  • Anacaulase-bcdb Topical Product SCDGP · 2662717

Brand-Name Concepts

  • 22000 MG anacaulase-bcdb 0.088 MG/MG Topical Gel [Nexobrid] SBD · 2626754
  • Anacaulase-bcdb 0.088 MG/MG [Nexobrid] SBDC · 2626753
  • Anacaulase Topical Gel [Nexobrid] SBDF · 2626746
  • Anacaulase-bcdb Topical Gel [Nexobrid] SBDFP · 2654459
  • Nexobrid Topical Product SBDG · 2626745
  • Nexobrid BN · 2626743

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 2626751 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69866-2002-03 1 KIT in 1 CARTON (69866-2002-3) * 20 g in 1 JAR (69866-20... NEXOBRID Vericel Corporation 2022-12-29
69866-2005-03 1 KIT in 1 CARTON (69866-2005-3) * 5 g in 1 VIAL, GLASS (6... NEXOBRID Vericel Corporation 2022-12-29
69866-2015-03 1 KIT in 1 CARTON (69866-2015-3) * 5 g in 1 VIAL, GLASS (6... NEXOBRID Vericel Corporation 2022-12-29
Observed labelers: Vericel Corporation (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.